Are Peptides Legal?

Buying raw peptide powder to study in a lab is not illegal. Selling an injectable peptide product for a person to use, on the other hand, is almost always selling an unapproved drug — and putting "research use only" on the label does not change that, according to the FDA's own enforcement record.

That gap between the two questions is where almost all the confusion lives. "Are peptides legal" has no single answer because "peptide" covers an approved prescription drug, a raw chemical nominated for pharmacy compounding, and an injectable sold online with a disclaimer, and US law treats those three very differently.

Approved drugs versus everything else

A handful of peptides are FDA-approved prescription drugs with a New Drug Application on file: injectable semaglutide and injectable tirzepatide (GLP-1 receptor agonists marketed by Novo Nordisk and Eli Lilly for type 2 diabetes and weight management), tesamorelin (a growth-hormone-releasing-hormone analog from Theratechnologies, approved for a specific HIV-related condition), and bremelanotide (from Palatin Technologies, approved for a sexual-dysfunction indication). For these, "legal" means exactly what it means for any prescription medicine: a doctor prescribes it, a licensed pharmacy dispenses it, and the approval covers the specific indication on the label — nothing else.

Nearly every other peptide sold online — BPC-157, TB-500, epitalon, semax, KPV, SS-31/elamipretide, and dozens more — has no FDA-approved application for human use at all. That does not make the molecule itself contraband; the amino acid sequence isn't scheduled like a controlled substance. What's unresolved is whether, and how, it can lawfully be turned into a product a person injects.

The compounding pathway, and why it's stuck mid-decision

One legal route for an unapproved peptide to reach a patient is pharmacy compounding under Section 503A of the Food, Drug and Cosmetic Act, which lets a compounding pharmacy prepare a drug from a bulk substance under a prescription. The FDA sorts substances nominated for that use into three informal categories, laid out on its Bulk Drug Substances Used in Compounding Under Section 503A page: Category 1 substances are ones the agency says it generally won't act against compounders for using; Category 2 covers substances with identified "significant safety concerns," where the agency says it will consider enforcement; and Category 3 covers nominations with too little data to evaluate yet. None of the three categories is the same as formal inclusion on the 503A bulks list, which only happens through federal rulemaking.

Several familiar peptides have spent 2026 moving between those boxes without landing anywhere final. On April 15, the FDA removed BPC-157, TB-500 and ten other peptides from Category 2 after their compounding nominations were withdrawn, according to a client alert from the law firm Frier Levitt. Removal from Category 2 does not put a substance into Category 1 or onto the bulks list — it just means the agency's stated safety objection to that specific nomination no longer applies. Then, on July 23–24, the FDA's Pharmacy Compounding Advisory Committee voted on whether to recommend six peptides — BPC-157, TB-500, KPV, MOTS-c, epitalon and semax — for the 503A bulks list; the committee voted yes on all six by narrow margins, over the objection of FDA's own scientific staff, per a summary from the law firm McDermott Will & Emery. A committee recommendation isn't a rule. The agency still has to run formal notice-and-comment rulemaking before any of the six could be legally compounded under Section 503A, and as of this writing none of them has been added to the list.

"Research use only" is a real label — for a different kind of product

Peptide sellers that don't go through a pharmacy often rely on a "research use only" or "not for human consumption" disclaimer. That phrase has an actual legal history, just not the one it's borrowed for here: the FDA's research-use-only framework, from a 2013 guidance document, governs in-vitro diagnostic products still in development and laboratory instruments and reagents meant for non-clinical research, according to a regulatory explainer from the Johner Institute. It was never written for an injectable substance sold to a consumer who intends to use it on themselves.

The FDA made that gap explicit on August 24, when its Center for Drug Evaluation and Research sent warning letters to five online peptide sellers, including one addressed to TXP Innovations LLC (doing business as Tex Peptides) and posted on fda.gov. The letter's reasoning doesn't turn on the disclaimer at all: it states that "despite statements on your product labeling" marketing the products "research use only," the rest of each website — including claims that semaglutide is "a valuable therapeutic candidate in obesity management" and that bremelanotide was "specifically researched for its ability to increase arousal and desire" — "establishes that your products are intended to be drugs for human use." The letter also treats the bacteriostatic water the company sold alongside its peptides as part of the same violation, because it supplied "the means to prepare an injectable drug for human administration." On that reasoning, cited in a client alert from the law firm ArentFox Schiff, a label is not a defense if the rest of the marketing describes a drug.

What about sports?

A separate rulebook governs competitive sport. The World Anti-Doping Agency's 2026 Prohibited List, which took effect January 1 and which WADA circulated to sport federations including World Rugby, bans an entire class called S2 — peptide hormones, growth factors and related mimetics — at all times, in and out of competition, with no exceptions for "specified substances." Unapproved peptides that don't fit neatly into S2, including BPC-157, are generally caught instead by S0, WADA's catch-all for any pharmacologically active substance without the regulatory approval needed for human therapeutic use anywhere in the world. Both categories carry the same at-all-times ban. (Where a peptide like semaglutide is an approved diabetes drug rather than an unapproved research compound, WADA's own committee has repeatedly declined to ban it outright — a separate and more contested debate covered in an earlier Journal post.)

What's actually settled versus still moving

What's settled: an FDA-approved peptide drug is legal under the same rules as any prescription medicine; an unapproved peptide sold as an injectable consumer product, with or without an RUO disclaimer, is what the FDA's own letters call it — an unregulated, unapproved new drug; and sport's anti-doping rules ban peptide hormones outright regardless of what any retailer calls them.

What isn't settled: whether any of the peptides the PCAC recommended in July will actually reach the 503A bulks list, and on what timeline, since formal rulemaking has not concluded. Separately, an earlier Journal post reported that administration officials have floated letting compounding pharmacies use some unapproved peptides without waiting for that rulemaking at all — a policy that, if adopted, would sit on top of the Section 503A framework rather than inside it, and that FDA's own staff have reportedly objected to. Enforcement also isn't uniform: the August warning letters targeted five specific sellers out of a much larger market, and individual state pharmacy boards have added their own restrictions independent of the FDA's categories.

What this means for researchers

For anyone evaluating a peptide as a research subject rather than a product to use, the legal status of the compound and the quality of the documentation behind a particular batch are two different questions, and 2026's enforcement actions have mostly been about the first one. A seller's "research use only" language says nothing about either; as the FDA's own letters show, the agency reads the whole site, not the disclaimer.

The compounding pathway that would eventually give some of these peptides a lawful route into a pharmacy is real, moving, and not finished. Tracking it means watching the FDA's rulemaking docket and PCAC meeting outcomes, not a single list that updates once. Readers who want the documentation side of the picture — how to tell a real lab report from a thin one, and what a lot number is actually supposed to prove — will find that covered in the Journal's guide to vetting a peptide vendor and the reading-lab-reports guide; neither one touches on legal status, which is a regulatory question, not a documentation one.